New medications 'revolutionary' for kids with atopic dermatitis

First approved for adults in 2017, dupilumab is now available for teenagers aged 12 to 17 years with moderate to severe AD who could not achieve control with other medications. According to Pfizer, both doses of the drug were well-tolerated, and no unanticipated safety events occurred during the tri...

Full description

Saved in:
Bibliographic Details
Published inInfectious diseases in children Vol. 32; no. 8; pp. 1 - 6
Main Author Bortz, Katherine
Format Journal Article
LanguageEnglish
Published Thorofare SLACK INCORPORATED 01.08.2019
Subjects
Children & youth
Chronic illnesses
Clinical medicine
Clinical trials
Dermatitis
Dermatology
Eczema
FDA approval
Immunology
Infectious diseases
Laboratories
Monoclonal antibodies
Pediatrics
Researchers
Rheumatoid arthritis
Steroids
Studies
Online AccessGet full text

Cover

More Information
Summary:First approved for adults in 2017, dupilumab is now available for teenagers aged 12 to 17 years with moderate to severe AD who could not achieve control with other medications. According to Pfizer, both doses of the drug were well-tolerated, and no unanticipated safety events occurred during the trial. According to Eichenfield, JAK inhibitors represent a new class of medication that can modulate specific cytokines involved in the pathophysiology of AD. According to Kirkorian, there are several reasons why a condition that did not previously have a booming drug pipeline would suddenly develop so much interest.
ISSN:1044-9779